-

Genetron Health Announces Forthcoming Unveiling of Its Cancer Research Papers at the AACR Annual Meeting

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health”), a China-based precision oncology company that covers full-cycle cancer care, announced that 14 cancer research papers will be presented as posters at the American Association for Cancer Research (AACR) 2020 Annual Meeting, which will take place virtually on April 27-28 and June 22-24.

In collaboration with over 10 notable cancer research centers and clinical hospitals in China, including the Chinese PLA General Hospital (301 Hospital), Cancer Hospital of Chinese Academy of Medical Sciences, Beijing Tiantan Hospital of Capital Medical University, Genetron Health’s presentation will cover a broad spectrum of precision oncology topics such as molecular and immunological diagnostics, bio-informatics analysis in multiple cancer types including lung cancer, gastric cancer, central nervous system tumors and urinary system tumors.

Scientists at Genetron Health with a multi-disciplinary background have devoted significant resources to continuously optimize key diagnostics technologies including liquid biopsy, fusion detection, and algorithms for bioinformatics. They focus on improving the quality and efficiency of sample testing, as well as the comprehensiveness and stability of bioinformatics analysis. Genetron Health has accumulated clinically valuable data in the fields of diagnostics, neoadjuvant chemotherapy prognosis and efficacy evaluation, immunotherapy, and drug resistance to facilitate translation into clinical applications.

Genetron Health actively collaborates with clinicians to drive cancer genomics research. The Company has published over 20 papers in Nature Genetics, Cancer Cell, Nature Communications, PNAS, and other internationally recognized academic journals, accelerating the clinical translation and commercialization of scientific research and continously improving the reliability and accessibility of its products and technology. Genetron Health is committed to making available advanced and reliable precision medicine technology to the community.

About the AACR

Founded in 1907, the American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the conquest of cancer. It has grown from its earliest 11 members to over 47,000 members in 127 countries and territories. The mission of AACR is to prevent and cure cancer through research, education, communication and collaboration. Through its programs and services, the AACR fosters research in cancer and related biomedical science; accelerates the dissemination of new research findings among scientists and others dedicated to the conquest of cancer; promotes science education and training; and advances the understanding of cancer etiology, prevention, diagnosis, and treatment throughout the world.The AACR Annual Meeting is one of the largest cancer research conferences in the world, attracting nearly 20,000 professionals from across the globe each year.

About Genetron Health

Genetron Health is a leading and fast-growing precision oncology company in China that aims to provide one-stop genomic profiling solutions for multiple scenarios covering early screening, diagnosis and monitoring, and biopharmaceutical services. The company collaborates with over 400 hospitals and dozens of biopharmaceutical companies and research institutions, and has developed a large proprietary genomic database.

Genetron Health has established R&D centers in both the United States and China, two manufacturing facilities with both ISO 13485:2016 certification and ISO 9001 2015 certification in China and five clinical laboratories in Beijing (CLIA accreditation and CAP certification), Shanghai, Hangzhou, Chongqing and Guangzhou. The R&D capacities of Genetron Health are supported by a best-in-class research and development team led by scientists at the forefront of cancer genomics research. The company has published many research papers in highly influential worldwide peer-reviewed scientific journals, such as Nature Genetics, Nature Communications, Cell Research and PNAS. For more information, please visit www.genetronhealth.com.

Contacts

For media inquiries, please contact:
Tao Yuan
E-mail: pr@genetronhealth.com

Genetron Holdings Limited


Release Versions

Contacts

For media inquiries, please contact:
Tao Yuan
E-mail: pr@genetronhealth.com

More News From Genetron Holdings Limited

Genetron Health Announces Strategic Partnership with Siemens Healthineers to Promote Precision Oncology for Lung Cancer

SHANGHAI--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced a strategic partnership with Siemens Healthineers at the China Medical Equipment Fair. This partnership aims to promote large scale application of Genetron’s S5 platform and lung cancer 8-gene IVD a...

Genetron Health Releases 22 New Research Results at American Association for Cancer Research Annual Meeting (AACR) 2021

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ:GTH), a leading precision oncology platform company in China that specializes in molecular profiling tests, early cancer screening products and companion diagnostics development, today announced the release of 22 research results at the American Association for Cancer Research Annual Meeting 2021 (AACR 2021). The results were from a series of studies that Genetron Health conducted with 13 leading hos...

Genetron Health Presented Its Proprietary Early Screening Technology Mutation Capsule at Science/AAAS Webinar

BEIJING--(BUSINESS WIRE)--Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH) sponsored a Science/AAAS Webinar, “Early cancer screening today and tomorrow: Exploring liquid biopsy profiling for diagnosis and treatment”, which launched today. During the panel discussion, Genetron Health’s Chief Technology Officer, Dr. Yuchen Jiao, gave a speech entitled “Profiling cfDNA-based Biomarkers for the Early Detection of Cancer”. In his presentation, Dr. Jiao highlighted the impo...
Back to Newsroom